PCT/IL2005/000232

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/11 A61K48/00 A61K31/7088 A61P35/00							
According to International Patent Classification (IPC) or to both national classification and IPC							
B. FIELDS	SEARCHED						
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N A61K A61P							
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched							
Electronic data base consulted during the International search (name of data base and, where practical, search terms used)							
EPO-Internal							
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT						
Category °	Citation of document, with indication, where appropriate, of the relevant	vant passages	Relevant to claim No.				
X	MADI L. ET AL.: "A3 Adenosine Recactivation in melanoma cells: assobetween receptor fate and tumor grutilizing siRNA" INTERNATIONAL JOURNAL OF MOLECULAL MEDICINE, vol. 12, no. supplement.1, 2003, XP008048581 Abstract 251: 8th World Congress advances in Oncology and 6th Intel Symposium on Molecular Medicine; Greece; October 16-18, 2003 the whole document	ociation rowth R page S42, on rnational	1-6,9-14				
X Further documents are listed in the continuation of box C. X Patent family members are listed in annex.							
"A" docume consider filing of the citation other the country to the citation of the citation o	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ant which may throw doubts on priority claim(s) or is cited to establish the publication date of another or other special reason (as specified) lent referring to an oral disclosure, use, exhibition or means	or priority date and not in conflict with to cited to understand the principle or the invention "X" document of particular relevance; the classification cannot be considered novel or cannot involve an inventive step when the document of particular relevance; the classification cannot be considered to involve an inventis combined with one or moments, such combination being obvious in the art.	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled				
Date of the	Date of the actual completion of the international search Date of malling of the international search report						
16 June 2005		30/06/2005					
Name and mailing address of the ISA		Authorized officer					
European Patent Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016		Macchia, G					



Intel Application No
PCT/IL2005/000232

	WALL DOCUMENTS CONSCIDEDED TO BE DELEVANT	FC171L2005/000232				
	cition) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.				
Category	Category • Citation of document, with indication, where appropriate, of the relevant passages					
A	MADI L. ET AL.: "A3 Adenosine Receptor activation in melanoma cells" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 43, 24 October 2003 (2003-10-24), pages 42121-42130, XP002332045 cited in the application the whole document					
A	OHANA G. ET AL.: "Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101" BRITISH JOURNAL OF CANCER, vol. 89, 2003, pages 1552-1558, XP002332046 the whole document					
A	WO 00/40251 A (CAN-FITE TECHNOLOGIES LTD. (IL); FISHMAN PNINA; COHN ILAN) 13 July 2000 (2000-07-13) the whole document					
А	MERIMSKY O. ET AL.: "Modulation of the A3 Adenosine Receptor by low agonist concentration induces antitumor and myelostimulatory effects" DRUG DEVELOPMENT RESEARCH, vol. 58, no. 4, April 2003 (2003-04), pages 386-389, XP009024519 ISSN: 0272-4391 the whole document					
A	FISHMAN P. ET AL.: "A3 adenosine receptor -as a target for cancer therapy" ANTI-CANCER DRUGS, vol. 13, no. 5, June 2002 (2002-06), pages 437-443, XP009024520 ISSN: 0959-4973 the whole document	·				



Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)				
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:				
Although claims 7, 9-12 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.				
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:				
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).				
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)				
This International Searching Authority found multiple inventions in this international application, as follows:				
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.				
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.				
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report				
covers only those claims for which fees were pald, specifically claims Nos.:				
4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:				
Remark on Protest				
No protest accompanied the payment of additional search fees.				

Information on patent family members

Inte

Application No

PCT/IL2005/000232

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0040251 A	13-07-2000	AU 757541 B2 AU 1888400 A CA 2356447 A1 EP 1140116 A1 WO 0040251 A1 JP 2002534390 T US 6638914 B1 US 2001031742 A1 US 2002037871 A1	27-02-2003 24-07-2000 13-07-2000 10-10-2001 13-07-2000 15-10-2002 28-10-2003 18-10-2001 28-03-2002